Zacks Small Cap Analysis – IMNN: Outcomes from OVATION 2 Examine in Mid-2024… Educated
By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Enterprise Replace Topline Knowledge from OVATION 2 Trial Anticipated in Mid-2024 Imunon, Inc. (NASDAQ:IMNN) is at present conducting the Section 1/2 OVATION 2 trial of IMNN-001, the corporate’s IL-12 gene-mediated immunotherapy that’s primarily based on the TheraPlas expertise. The OVATION 2 examine is evaluating … Read more